Mauritius

Reimbursed Care Access

Mauritius maintains stringent controls on classical psychedelic compounds: most serotonergic psychedelics (psilocybin/psilocin, DMT, mescaline, MDMA, 5‑MeO‑DMT, 2C‑X, etc.) are listed in the national Dangerous Drugs Act schedules and are prohibited outside very narrow authorised medical, forensic or research exceptions. Ketamine is controlled but remains an authorised medicinal anaesthetic subject to strict regulatory controls and prescription limits; newer commercial esketamine (Spravato) does not appear on public registration lists and is not a reimbursed option in routine care. Overall there is no established reimbursed psychedelic therapy pathway in public insurance and access is limited to regulated medical use (ketamine anaesthesia), tightly supervised authorised research, or exceptional authorised imports by the Permanent Secretary/Pharmacy Board. [https://mauritiuslii.org/akn/mu/act/2000/41/eng%402017-06-30|Dangerous Drugs Act (Mauritius)], [https://nds.govmu.org/nds/|National Drug Secretariat (Mauritius)].